
Sign up to save your podcasts
Or


Dr. Hobbs joins the podcast to discuss the latest advances in myeloproliferative neoplasms (MPNs), including ropeginterferon and the VERIFY trial of rusfertide in polycythemia vera. He highlights key efficacy and safety data, unmet needs in essential thrombocythemia and myelofibrosis, and the next wave of clinical trials to watch.
By Rahul Banerjee, MD4.8
2727 ratings
Dr. Hobbs joins the podcast to discuss the latest advances in myeloproliferative neoplasms (MPNs), including ropeginterferon and the VERIFY trial of rusfertide in polycythemia vera. He highlights key efficacy and safety data, unmet needs in essential thrombocythemia and myelofibrosis, and the next wave of clinical trials to watch.

140 Listeners

324 Listeners

498 Listeners

76 Listeners

120 Listeners

28 Listeners

1,144 Listeners

187 Listeners

22 Listeners

369 Listeners

52 Listeners

138 Listeners

48 Listeners

193 Listeners

29 Listeners